文献速递神经肿瘤

CBTRUS统计报告:美国脑肿瘤协会与美国国家癌症研究所神经肿瘤学分部——2016至2020年美国诊断的青少年和青年原发性脑及其他中枢神经系统肿瘤

CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020.
PubMed 文献 · Neuro Oncol · 2024-01-01

本报告分析了2016至2020年美国15-39岁青少年和青年(AYA)原发性脑及其他中枢神经系统肿瘤的流行病学,首次提供按组织病理学分类的分子标志物统计和患病率。AYA中原发性恶性肿瘤和非恶性肿瘤的年均年龄别发病率为12.00/10万,年均新诊断12,848例;原发性恶性肿瘤年均死亡1,018例,年均年龄别死亡率为0.96/10万。垂体瘤最常见(36.6%),弥漫性胶质瘤是最常见的分子定义肿瘤(年龄别发病率1.51/10万)。

要点

  • 2016-2020年AYA原发性脑及中枢神经系统肿瘤年均发病率为12.00/10万,年均新诊断12,848例。
  • 垂体瘤最常见(36.6%),年龄别发病率4.34/10万;弥漫性胶质瘤是最常见的分子定义肿瘤(1.51/10万)。
  • 原发性恶性脑肿瘤是AYA人群第二常见癌症死因,年均死亡率0.96/10万。

核心结论

  • 2016至2020年美国AYA原发性脑及其他中枢神经系统肿瘤年均年龄别发病率为12.00/10万,年均新诊断12,848例;原发性恶性肿瘤年均死亡1,018例,年均年龄别死亡率为0.96/10万。
  • 原发性恶性脑肿瘤是AYA人群第二常见癌症死因;总体及特定组织病理学发病率随年龄显著变化。

研究设计与样本

  • 本报告为美国中央脑肿瘤登记处(CBTRUS)与美国脑肿瘤协会2016年出版物的更新,对2016至2020年美国诊断的15-39岁AYA原发性脑及其他中枢神经系统肿瘤进行流行病学分析,首次提供按组织病理学分类的分子标志物统计和患病率。

主要发现

  • 2016至2020年AYA原发性恶性和非恶性脑及其他中枢神经系统肿瘤年均年龄别发病率为12.00/10万,年均新诊断12,848例。
  • 同期AYA原发性恶性脑肿瘤年均死亡1,018例,年均年龄别死亡率为0.96/10万。
  • 按组织病理学分类,垂体瘤最常见(36.6%),年龄别发病率为4.34/10万;总体发病率随年龄增长而增加,各年龄段女性发病率均高于男性。
  • 所有原发性脑肿瘤合计及仅非恶性肿瘤的发病率在非西班牙裔美洲印第安人/阿拉斯加原住民中最高,而恶性肿瘤在非西班牙裔白人个体中较其他种族/族裔组更常见。
  • 按组织病理学分类,最常见的分子定义肿瘤为弥漫性胶质瘤(年龄别发病率1.51/10万)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent analyses have shown that, whereas cancer survival overall has been improving, it has not improved for adolescents and young adults ages 15-39 years (AYA). The clinical care of AYA with primary brain and other central nervous system (CNS) tumors (BT) is complicated by the fact that the histopathologies of such tumors in AYA differ from their histopathologies in either children (ages 0-14 years) or older adults (ages 40+ years). The present report, as an update to a 2016 publication from the Central Brain Tumor Registry of the United States and the American Brain Tumor Association, provides in-depth analyses of the epidemiology of primary BT in AYA in the United States and is the first to provide biomolecular marker-specific statistics and prevalence by histopathology for both primary malignant and non-malignant BT in AYA. Between 2016 and 2020, the annual average age-specific incidence rate (AASIR) of primary malignant and non-malignant BT in AYA was 12.00 per 100,000 population, an average of 12,848 newly diagnosed cases per year. During the same period, an average of 1,018 AYA deaths per year were caused by primary malignant BT, representing an annual average age-specific mortality rate of 0.96 per 100,000 population. When primary BT were categorized by histopathology, pituitary tumors were the most common (36.6%), with an AASIR of 4.34 per 100,000 population. Total incidence increased with age overall; when stratified by sex, the incidence was higher in females than males at all ages. Incidence rates for all primary BT combined and for non-malignant tumors only were highest for non-Hispanic American Indian/Alaska Native individuals, whereas malignant tumors were more frequent in non-Hispanic White individuals, compared with other racial/ethnic groups. On the basis of histopathology, the most common molecularly defined tumor was diffuse glioma (an AASIR of 1.51 per 100,000). Primary malignant BT are the second most common cause of cancer death in the AYA population. Incidence rates of primary BT overall, as well as specific histopathologies, vary significantly by age. Accordingly, an accurate statistical assessment of primary BT in the AYA population is vital for better understanding the impact of these tumors on the US population and to serve as a reference for afflicted individuals, for researchers investigating new therapies, and for clinicians treating these patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Price M, Neff C, Nagarajan N, et al. CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2024. PMID: 38709657. doi:10.1093/neuonc/noae047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。